Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:IMRA

IMARA (IMRA) Stock Price, News & Analysis

IMARA logo

About IMARA Stock (NASDAQ:IMRA)

Key Stats

Today's Range
N/A
50-Day Range
$6.32
$25.28
52-Week Range
N/A
Volume
271,700 shs
Average Volume
138,364 shs
Market Capitalization
$165.80 million
P/E Ratio
126.40
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Receive IMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMARA and its competitors with MarketBeat's FREE daily newsletter.

IMRA Stock News Headlines

Imara Blume
Buffett Dumps $982 Million in BofA Stock—What Does He Know?
Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.
Imara 10% Owner Trades $336K In Company Stock
See More Headlines

IMRA Stock Analysis - Frequently Asked Questions

IMARA Inc. (NASDAQ:IMRA) released its earnings results on Tuesday, November, 9th. The company reported ($2.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.64) by $1.44.

IMARA shares reverse split before market open on Friday, February 24th 2023. The 1-4 reverse split was announced on Friday, February 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

IMARA (IMRA) raised $76 million in an initial public offering (IPO) on Thursday, March 12th 2020. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Citigroup and SVB Leerink acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that IMARA investors own include NIO (NIO), Novavax (NVAX), NVIDIA (NVDA), Axsome Therapeutics (AXSM), Alibaba Group (BABA), AMC Entertainment (AMC) and BioXcel Therapeutics (BTAI).

Company Calendar

Last Earnings
11/09/2021
Today
11/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMRA
Phone
N/A
Fax
N/A
Employees
41
Year Founded
N/A

Profitability

Net Income
$1.49 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.44 per share

Miscellaneous

Free Float
16,449,000
Market Cap
$165.80 million
Optionable
Not Optionable
Beta
1.09
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:IMRA) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners